We can’t show the full text here under this license. Use the link below to read it at the source.
CAR-T cells in solid tumors: Challenges and breakthroughs
CAR-T cell therapy for solid tumors: obstacles and recent progress
AI simplified
Abstract
Chimeric antigen receptor (CAR)-T cell therapy has shown limited efficacy in solid tumors due to multiple challenges.
- Key obstacles include insufficient CAR-T cell movement to tumors and limited growth and survival of these cells.
- Tumor relapse may occur because of antigen loss or variability among tumor cells.
- The immunosuppressive environment of tumors is associated with reduced effectiveness of CAR-T cell functions.
- Recent clinical trials in advanced solid tumors have provided insights into overcoming these challenges.
- Innovative strategies involve integrating synthetic biology and gene engineering to improve CAR-T cell capabilities and target multiple antigens.
AI simplified